arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Fortress Biotech, Inc.

FBIO
$2.69 ▼ -0.09 (-3.42%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
74 Visible periods
33 Metrics
Peer-ranked Benchmarks
Price Chart
40
Health
Weak
Moderately Bullish
auto_awesome

Analytical Summary

Fortress Biotech, Inc. demonstrates solid fundamentals with strength in Return on Common Equity (%). Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $84.8M
Dividend Yield
Revenue Growth 22.1%
Op. Margin -48.3%
ROIC -3.7%
FCF / Share $6.46
Trailing P/E 0.8x
Price / Book 0.6x
FCF Yield 240.3%
Debt / Equity 0.23
info Valuation on last close. End-of-day price, Aug 7, 2026.

74-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$16.04M
↑ +22.1%
Net Income Profit after all expenses
$110.37M
↑ +2903.5%
Operating Margin Operating profit as % of sales
-48.3%
↓ -62.0% 2th
FCF / Share Free cash flow per share
$6.46
↑ +2981.9%
Long-Term Debt Long-term obligations
$37.50M
↓ -28.5%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability
24
Returns
78
Financial Health
31
Cash Quality
2

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 21 years · 74 quarters